Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthias Wirth

Showing results (31-40 of 63) with videos related to

Pageof 7
Sort By:
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|April 7, 2021
Important role of Nfkb2 in the Kras<sup>G12D</sup>-driven carcinogenesis in the pancreasZonera Hassan, Christian Schneeweis, Matthias Wirth, et al.
Molecular Cancer Therapeutics|November 26, 2025
The histone modifier KANSL2 is an actionable biomarker in multiple myelomaKaiting Jiang, Marieluise Kirchner, Frederik Herzberg, et al.
Nature Communications|December 8, 2023
Characterization of nucleolar SUMO isopeptidases unveils a general p53-independent checkpoint of impaired ribosome biogenesisJudith Dönig, Hannah Mende, Jimena Davila Gallesio, et al.
Cancer Communications (London, England)|March 7, 2022
Indirect targeting of MYC sensitizes pancreatic cancer cells to mechanistic target of rapamycin (mTOR) inhibitionChristian Schneeweis, Zonera Hassan, Katja Ascherl, et al.
Oncotarget|May 21, 2016
Membranous CD24 drives the epithelial phenotype of pancreatic cancerClara Lubeseder-Martellato, Ana Hidalgo-Sastre, Carolin Hartmann, et al.
United European Gastroenterology Journal|September 16, 2025
Pan-ERBB Inhibitors Synergize With KRAS Inhibitors in Rectal CancerJonas Buchloh, Melanie Spitzner, Hauke Zimmermann, et al.
The EMBO Journal|September 5, 2022
The OTUD6B-LIN28B-MYC axis determines the proliferative state in multiple myelomaCarmen Paulmann, Ria Spallek, Oleksandra Karpiuk, et al.
EMBO Molecular Medicine|July 24, 2023
Actionable loss of SLF2 drives B-cell lymphomagenesis and impairs the DNA damage responseLe Zhang, Matthias Wirth, Upayan Patra, et al.
British Journal of Cancer|February 1, 2018
MTOR inhibitor-based combination therapies for pancreatic cancerZonera Hassan, Christian Schneeweis, Matthias Wirth, et al.
Cellular and Molecular Life Sciences : CMLS|December 19, 2022
AP1/Fra1 confers resistance to MAPK cascade inhibition in pancreatic cancerChristian Schneeweis, Sandra Diersch, Zonera Hassan, et al.
Pageof 7

Showing results (31-40 of 63) with videos related to

Sort By:
Pageof 7
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|April 7, 2021
Important role of Nfkb2 in the Kras<sup>G12D</sup>-driven carcinogenesis in the pancreasZonera Hassan, Christian Schneeweis, Matthias Wirth, et al.
Molecular Cancer Therapeutics|November 26, 2025
The histone modifier KANSL2 is an actionable biomarker in multiple myelomaKaiting Jiang, Marieluise Kirchner, Frederik Herzberg, et al.
Nature Communications|December 8, 2023
Characterization of nucleolar SUMO isopeptidases unveils a general p53-independent checkpoint of impaired ribosome biogenesisJudith Dönig, Hannah Mende, Jimena Davila Gallesio, et al.
Cancer Communications (London, England)|March 7, 2022
Indirect targeting of MYC sensitizes pancreatic cancer cells to mechanistic target of rapamycin (mTOR) inhibitionChristian Schneeweis, Zonera Hassan, Katja Ascherl, et al.
Oncotarget|May 21, 2016
Membranous CD24 drives the epithelial phenotype of pancreatic cancerClara Lubeseder-Martellato, Ana Hidalgo-Sastre, Carolin Hartmann, et al.
United European Gastroenterology Journal|September 16, 2025
Pan-ERBB Inhibitors Synergize With KRAS Inhibitors in Rectal CancerJonas Buchloh, Melanie Spitzner, Hauke Zimmermann, et al.
The EMBO Journal|September 5, 2022
The OTUD6B-LIN28B-MYC axis determines the proliferative state in multiple myelomaCarmen Paulmann, Ria Spallek, Oleksandra Karpiuk, et al.
EMBO Molecular Medicine|July 24, 2023
Actionable loss of SLF2 drives B-cell lymphomagenesis and impairs the DNA damage responseLe Zhang, Matthias Wirth, Upayan Patra, et al.
British Journal of Cancer|February 1, 2018
MTOR inhibitor-based combination therapies for pancreatic cancerZonera Hassan, Christian Schneeweis, Matthias Wirth, et al.
Cellular and Molecular Life Sciences : CMLS|December 19, 2022
AP1/Fra1 confers resistance to MAPK cascade inhibition in pancreatic cancerChristian Schneeweis, Sandra Diersch, Zonera Hassan, et al.
Pageof 7